Karas Eric
SEC CIK 1951287 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| SPRY | ARS Pharmaceuticals, Inc. | Chief Commercial Off | 37.2K | — | $1.31M | 14 | 2024-08-19 | 2026-06-12 |
Most active insiders at SPRY, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Chakma Justin | Chief Business Off | — | $1.48M |
| 2 | Karas Eric | Chief Commercial Off | — | $250.0K |
| 3 | Dorsey Brian | COO | — | $190.1K |
| 4 | Fitzpatrick Alexander A | CLO | — | $33.5K |
| 5 | Shah Pratik | Dir | — | — |
Transactions 14
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-12 20:06 | 2026-06-12 | SPRY | ARS Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Off | M - OptEx | $1.50 | +25.0K | 37.2K | +205% | +$37.5K |
| DT | 2026-06-12 20:06 | 2026-06-12 | SPRY | ARS Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Off | S - Sale+OE | $10.00 | -25.0K | 12.2K | -67% | -$250.0K |
| D | 2025-07-03 | 2025-07-01 | SPRY | ARS Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Off | M - OptEx | $1.50 | +15.0K | 25.3K | +145% | +$22.5K |
| D | 2025-07-03 | 2025-07-01 | SPRY | ARS Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Off | S - Sale+OE | $16.99 | -15.0K | 10.3K | -59% | -$254.8K |
| D | 2025-06-20 | 2025-06-18 | SPRY | ARS Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Off | S - Sale+OE | $16.00 | -15.0K | 7,696 | -66% | -$240.0K |
| D | 2025-06-20 | 2025-06-18 | SPRY | ARS Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Off | M - OptEx | $1.50 | +15.0K | 22.7K | +195% | +$22.5K |
| D | 2025-03-21 | 2025-03-20 | SPRY | ARS Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Off | M - OptEx | $1.50 | +10.0K | 17.7K | +130% | +$15.0K |
| D | 2025-03-21 | 2025-03-20 | SPRY | ARS Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Off | S - Sale+OE | $14.00 | -10.0K | 7,696 | -57% | -$140.0K |
| DM | 2024-12-04 | 2024-12-02+ | SPRY | ARS Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Off | S - Sale+OE | $14.04 | -10.0K | 5,693 | -64% | -$140.4K |
| DM | 2024-12-04 | 2024-12-02+ | SPRY | ARS Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Off | M - OptEx | $1.50 | +10.0K | 9,410 | New | +$15.0K |
| D | 2024-09-19 | 2024-09-18 | SPRY | ARS Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Off | S - Sale+OE | $14.00 | -10.0K | 5,693 | -64% | -$140.0K |
| D | 2024-09-19 | 2024-09-18 | SPRY | ARS Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Off | M - OptEx | $1.50 | +10.0K | 15.7K | +176% | +$15.0K |
| D | 2024-08-21 | 2024-08-19 | SPRY | ARS Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Off | M - OptEx | $1.50 | +10.0K | 15.7K | +176% | +$15.0K |
| D | 2024-08-21 | 2024-08-19 | SPRY | ARS Pharmaceuticals, Inc. | Karas Eric | Chief Commercial Off | S - Sale+OE | $14.00 | -10.0K | 5,693 | -64% | -$140.0K |
Purchase Sale Sale after option exercise All abbreviations